Christopher Primiano Net Worth

The estimated Net Worth of Christopher Brett Primiano is at least $2.72 millió dollars as of 1 December 2020. Mr. Primiano owns over 137,061 units of Karyopharm Therapeutics Inc stock worth over $46,960 and over the last 11 years he sold KPTI stock worth over $1,050,232. In addition, he makes $1,623,350 as Executive Vice President, Chief Business Officer és General Counsel and Secretary at Karyopharm Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Primiano KPTI stock SEC Form 4 insiders trading

Christopher has made over 23 trades of the Karyopharm Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 137,061 units of KPTI stock worth $1,428,176 on 1 December 2020.

The largest trade he's ever made was exercising 137,061 units of Karyopharm Therapeutics Inc stock on 1 December 2020 worth over $1,428,176. On average, Christopher trades about 9,303 units every 70 days since 2014. As of 1 December 2020 he still owns at least 63,460 units of Karyopharm Therapeutics Inc stock.

You can see the complete history of Mr. Primiano stock trades at the bottom of the page.

Christopher Primiano biography

Christopher B. Primiano J.D. serves as Executive Vice President, Chief Business Officer, General Counsel and Secretary of the Company. Mr. Primiano joined Karyopharm in March 2014 as Vice President, Corporate Development, General Counsel and Secretary, and was appointed Senior Vice President, Corporate Development, General Counsel and Secretary in September 2015; Senior Vice President, Operations, Business Development, General Counsel and Secretary in November 2016 and Executive Vice President, Chief Business Officer, General Counsel and Secretary in January 2018. Prior to joining Karyopharm, Mr. Primiano was a Counsel at Wilmer Cutler Pickering Hale and Dorr LLP, where he had practiced law since October 2012. From August 2010 to August 2012, he served as Vice President, Corporate Development, General Counsel and Secretary of GlassHouse Technologies, Inc., an information technology consulting company, where he led global legal operations and managed asset and subsidiary acquisition and sale activity. Mr. Primiano began his career at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP, where he practiced law from August 2006 to July 2010. Mr. Primiano received a B.A. in Political Economy and English from Georgetown University, an M.B.A. from the Boston College Carroll School of Management and a J.D. from Boston College Law School.

What is the salary of Christopher Primiano?

As the Executive Vice President, Chief Business Officer és General Counsel and Secretary of Karyopharm Therapeutics Inc, the total compensation of Christopher Primiano at Karyopharm Therapeutics Inc is $1,623,350. There are 3 executives at Karyopharm Therapeutics Inc getting paid more, with Ran Frenkel having the highest compensation of $6,481,860.

How old is Christopher Primiano?

Christopher Primiano is 39, he's been the Executive Vice President, Chief Business Officer és General Counsel and Secretary of Karyopharm Therapeutics Inc since 2017. There are 23 older and no younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.

What's Christopher Primiano's mailing address?

Christopher's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.

Insiders trading at Karyopharm Therapeutics Inc

Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic... és Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.

What does Karyopharm Therapeutics Inc do?

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

Complete history of Mr. Primiano stock trades at Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc executives and stock owners

Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ran Frenkel,
  Chief Development Operations Officer
• Michael Kauffman,
  Co-Founder, Chief Executive Officer and Director
• Sharon Shacham,
  President, Chief Scientific Officer
• Christopher Primiano,
  Executive Vice President, Chief Business Officer, General Counsel and Secretary
• Dr. Michael G. Kauffman M.D., Ph.D.,
  Co-Founder, Sr. Clinical Advisor & Director
• Dr. Michael G. Kauffman,
  Co-Founder, Sr. Clinical Advisor & Director
• Dr. Sharon Shacham M.B.A., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Dr. Sharon Shacham,
  Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board
• Michael P. Mason CPA, M.B.A.,
  Sr. VP, CFO & Treasurer
• Mansoor Mirza,
  Director and Clinical Advisor
• Barry Greene,
  Lead Independent Director
• Deepa Pakianathan,
  Independent Director
• Garen Bohlin,
  Independent Director
• Dr. Mansoor Raza Mirza M.D.,
  Clinical Consultant, Member of Scientific Advisory Board & Independent Director
• Mikael Dolsten,
  Independent Director
• Dr. Mansoor Raza Mirza,
  Clinical Consultant, Member of Scientific Advisory Board & Director
• Richard A. Paulson M.B.A.,
  Pres, CEO & Director
• Richard Paulson,
  Independent Director
• Christy Oliger,
  Director
• Perry Monaco,
  Senior Vice President of Sales
• Jatin Shah,
  Executive Vice President, Chief Medical Officer
• Tanya Lewis,
  Executive Vice President, Chief Regulatory Officer and Quality Officer
• Michael Mason,
  Chief Financial Officer, Senior Vice President, Treasurer
• James Accumanno J.D.,
  Chief Compliance Officer
• Elhan Webb C.F.A.,
  Sr. VP of Investor Relations
• Lisa Meletta J.D.,
  VP of Legal & Chief Compliance Officer
• Michael J. Mano J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Pierre S. Sayad M.S., Ph.D.,
  VP of Global Medical & Scientific Affairs
• Cameron Peters,
  VP of Fin., Assistant Treasurer & Principal Accounting Officer
• Ran Frenkel R.Ph., RPh,
  Exec. VP & Chief Devel. Officer
• Zhen Su,
  
• Carsten Thiel,
  Director
• Kenneth E Weg,
  Director
• J. Scott Garland,
  Director
• Justin A Renz,
  EVP, CFO & Treasurer
• Michael Falvey,
  EVP, CFO & Treasurer
• Peter Honig,
  Director
• Anand Varadan,
  EVP, Chief Commercial Officer
• Cameron Peters,
  VP of Finance
• Marcin Hadjimichael Andreas...,
  
• Paul Brannelly,
  SVP, FIN & ADMIN, SEC & TRES
• Ltd Czernik Marcin Hadjimic...,
  
• Ltd Czernik Marcin Hadjimic...,
  
• John Demaree,
  Chief Commercial Officer
• Deepika Pakianathan,
  
• Chen Schor,
  
• Stephen Mitchener,
  SVP, Chief Business Officer
• Michael Mano,
  SVP, General Counsel&Secretary
• Sohanya Roshan Cheng,
  EVP & Chief Commercial Officer
• Stuart Poulton,
  EVP, Chief Development Officer
• Reshma Rangwala,
  EVP & Chief Medical Officer